Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Entecavir is a prescription hepatitis B virus nucleoside analogue reverse transcriptase inhibitor. It treats chronic hepatitis B infection in adults and children age 2 and older who have active viral replication with persistent liver enzyme elevations or histologically active disease. Tablets come in 0.5 mg and 1 mg strengths.
read more about entecavir ...Inside cells, entecavir is converted to entecavir triphosphate. This active form competes with the natural nucleotide substrate used by hepatitis B reverse transcriptase and interferes with viral DNA priming, reverse transcription of the negative DNA strand, and synthesis of the positive DNA strand.
Entecavir is used for chronic hepatitis B infection from age 2 when there is evidence of active viral replication plus persistent ALT or AST elevation or histologically active disease. Pediatric dosing is based on body weight. Adults with lamivudine resistance or decompensated liver disease use a higher labeled dose.
Treatment-naive adults and adolescents age 16 and older with compensated liver disease take 0.5 mg once daily. Adults with lamivudine resistance or decompensated liver disease take 1 mg once daily. Tablets are taken on an empty stomach at least two hours after a meal and two hours before the next meal.
Entecavir carries boxed warnings for severe hepatitis B exacerbations after treatment stops, development of HIV resistance when untreated HIV and HBV coinfection is present, and lactic acidosis with severe hepatomegaly and steatosis. Kidney impairment with creatinine clearance below 50 mL per minute requires dose or interval adjustment.
Entecavir treats chronic hepatitis B infection under viral replication and liver disease criteria.
Most labeled adult regimens use once-daily dosing.
No. Tablets are taken on an empty stomach at least two hours before and after food.
Yes. Severe acute hepatitis B exacerbations have occurred after anti-hepatitis B treatment was discontinued.
BARACLUDE (Entecavir) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=professional&setid=046e61c9-9298-4b2e-b76e-b26b81fecd20. Date Accessed September 29, 2026.
Entecavir. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. https://www.ncbi.nlm.nih.gov/books/NBK548075/. Date Accessed September 29, 2026.
Entecavir: A Review of Its Use in Chronic Hepatitis B. https://pubmed.ncbi.nlm.nih.gov/19496629/. Date Accessed September 29, 2026.
Entecavir: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a605028.html. Date Accessed September 29, 2026.
Entecavir Versus Lamivudine for Patients With HBeAg-Negative Chronic Hepatitis B. https://pubmed.ncbi.nlm.nih.gov/16525138/. Date Accessed September 29, 2026.